AlphaTON Capital Sells Biotech Unit iOx Therapeutics to Immunova for Upfront Cash and Milestones
Event summary
- AlphaTON Capital has executed a binding call option to sell its biotech subsidiary iOx Therapeutics to Immunova for an upfront cash payment, 10% equity in the acquiring entity, milestone payments potentially exceeding $100 million, and single-digit royalties on future net sales.
- iOx’s lead candidate, PORT-2 (IMM60), has shown preliminary signs of anti-tumor activity in Phase 1/2 trials for advanced melanoma and metastatic NSCLC patients.
- The transaction is subject to Immunova securing financing commitments and customary closing conditions.
- AlphaTON will maintain significant participation in iOx’s future success through its equity stake, milestone payments, and royalty structure.
The big picture
AlphaTON Capital’s sale of iOx Therapeutics reflects a strategic pivot away from legacy biotech assets toward its core focus on scaling the Telegram super app. The deal underscores the company’s efforts to unlock value while maintaining participation in future success through equity and milestone-based payments. This move aligns with broader trends in tech conglomerates streamlining portfolios to enhance operational efficiency and investor returns.
What we're watching
- Deal Completion Risk
- Whether Immunova can secure the necessary financing to exercise the call option and complete the acquisition.
- Milestone Achievement
- The pace at which iOx’s pipeline achieves specified milestones to trigger potential payments exceeding $100 million.
- Strategic Focus Shift
- How AlphaTON will allocate resources to its mesothelioma program and new Telegram-oriented, AI-driven biotech initiative following the divestiture.
Related topics